Floatz logo

Adriamycin

Cognitive Impairment - Coarse Facies - Heart Defects - Obesity - Pulmonary Involvement - Short Stature - Skeletal Dysplasia Syndrome

Fudan UniversitySmall moleculePhase 2Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

5 Active assets in the Cognitive Impairment - Coarse Facies - Heart Defects - Obesity - Pulmonary Involvement - Short Stature - Skeletal Dysplasia Syndrome cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
Fudan University
Phase 2B
Prednisone
Fudan University
Phase 2B
(+)-Vincristine
Fudan University
Phase 2B
Lenalidomide
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2CCC
Parsaclisib
Fudan University
Phase 1/2CCC

Same molecule, other indications

Adriamycin is also rated in:

adult acute lymphoblastic leukemiaActive
BBB
Indicative · Phase 4
77 / 100
View asset →
B-cell childhood acute lymphoblastic leukemiaDormant
BBB
Indicative · Phase 3
76 / 100
View asset →
hematopoietic and lymphoid system neoplasmActive
BBB
Indicative · Phase 4
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →